8-K: Cocrystal Pharma Announces Second Quarter 2024 Results and Provides Clinical Program Updates

Cocrystal Pharma reported its second quarter 2024 financial results and provided updates on its antiviral drug development programs, including progress on its influenza and norovirus/coronavirus candidates.

Summary

• Cocrystal Pharma released its financial results for the second quarter of 2024, showing a net loss of $5.3 million, or $0.54 per share, compared to a net loss of $4.2 million, or $0.41 per share, in the same quarter of 2023.
• Research and development expenses increased to $4.3 million in Q2 2024 from $2.8 million in Q2 2023, primarily due to the advancement of CC-42344 into a Phase 2a clinical study and CDI-988 into a Phase 1 clinical study.
• General and administrative expenses decreased to $1.1 million in Q2 2024 from $1.5 million in Q2 2023, mainly due to lower legal expenses.
• For the first six months of 2024, the net loss was $9.3 million, or $0.91 per share, compared to a net loss of $9.4 million, or $1.03 per share, for the same period in 2023.
• The company's cash balance was $18.1 million as of June 30, 2024, down from $26.4 million at the end of 2023.
• Cocrystal expects to report topline results from the Phase 2a influenza A human challenge study with oral CC-42344 in 2025 and from the Phase 1 study with oral CDI-988 in late 2024 or early 2025.
• The company also plans to initiate a Phase 1 study with inhaled CC-42344 in 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the progress in clinical trials and the potential of the company's antiviral candidates. However, the increased net loss and decreased cash balance temper the overall positive outlook.

Positives

• The company has made progress in its clinical programs, with both CC-42344 and CDI-988 advancing through clinical trials.
• In vitro testing has shown that CC-42344 is effective against the avian influenza A (H5N1) PB2 protein.
• The company expects its current cash balance to be sufficient to fund its planned development programs for the next 12 months.
• The company has reported favorable safety and tolerability data from the single-ascending dose portion of the CDI-988 Phase 1 study.

Negatives

• The company's net loss increased in Q2 2024 compared to Q2 2023.
• The company's cash balance decreased from $26.4 million at the end of 2023 to $18.1 million as of June 30, 2024.
• Research and development expenses have increased, reflecting the costs of advancing clinical trials.

Risks

• The company's future results are subject to risks and uncertainties, including those related to clinical trials, regulatory approvals, and competition.
• The company's ability to execute its clinical and regulatory goals is dependent on the performance of its CROs and CMOs.
• The company's programs could be impacted by global economic factors, including high interest rates, inflation, and geopolitical conflicts.
• There is a risk of potential mutations in the viruses targeted by the company's product candidates, which could lead to resistance.

Future Outlook

Cocrystal Pharma expects to report topline results from the Phase 2a study of CC-42344 in 2025 and from the Phase 1 study of CDI-988 in late 2024 or early 2025. The company also plans to initiate a Phase 1 study with inhaled CC-42344 in 2025 and expects its cash to be sufficient to advance its planned development programs through the coming 12 months.

Management Comments

• Sam Lee, Ph.D., President and co-CEO of Cocrystal, stated that the company is rapidly approaching major inflection points in its clinical programs.
• James Martin, CFO and co-CEO of Cocrystal, stated that the company expects its cash to be sufficient to advance its planned development programs through the coming 12 months.

Industry Context

The announcement comes amid ongoing global concerns about influenza, norovirus, and coronavirus infections, highlighting the need for effective antiviral treatments. Cocrystal's focus on broad-spectrum antivirals aligns with the industry's push for solutions that can address both current and emerging viral threats. The company's approach of targeting conserved regions of viral enzymes is a strategy that is gaining traction in the antiviral drug development space.

Comparison to Industry Standards

• Cocrystal's approach of using structure-based drug discovery differs from traditional methods, potentially leading to more efficient drug development.
• The company's focus on broad-spectrum antivirals is similar to other companies in the space, such as Gilead Sciences and Regeneron, who are also developing treatments for multiple viral strains.
• The company's progress with CC-42344 and CDI-988 is comparable to other companies in early-stage clinical trials for antiviral drugs.
• The company's cash burn rate is typical for a clinical-stage biotech company, but the decrease in cash balance is a point of concern.
• The company's net loss per share is within the range of other biotech companies at a similar stage of development.

Related Party Transactions

• Operating lease right-of-use assets include $11 and $42 to related party.
• Current maturities of operating lease liabilities include $10 and $42 to related party.
• Long-term operating lease liabilities include $0 and $0 to related party.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and decreased cash balance.
• Employees may be encouraged by the progress in clinical trials and the company's future prospects.
• Customers and suppliers may be interested in the potential of the company's antiviral candidates.
• Creditors may be monitoring the company's financial performance and cash position.

Next Steps

• The company expects to report topline results from the Phase 2a influenza A human challenge study with oral CC-42344 in 2025.
• The company expects to report topline results from the Phase 1 study with oral CDI-988 in late 2024 or early 2025.
• The company plans to initiate a Phase 1 study with inhaled CC-42344 in 2025.
• The company plans to file an IND application in 2025 to conduct a late-stage study in the U.S. for CC-42344.

Key Dates

Keywords

antiviral, influenza, norovirus, coronavirus, clinical trials, CC-42344, CDI-988, drug development, biotechnology, Phase 2a, Phase 1